Local levonorgestrel regulation of androgen receptor and 17 -hydroxysteroid dehydrogenase type 2 expression in human endometrium
Author(s) -
Kevin A Burton,
Teresa A. Henderson,
Stephen G. Hillier,
J. Ian Mason,
Fouad K. Habib,
Robert Brenner,
Hilary Critchley
Publication year - 2003
Publication title -
human reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.446
H-Index - 226
eISSN - 1460-2350
pISSN - 0268-1161
DOI - 10.1093/humrep/deg510
Subject(s) - endometrium , levonorgestrel , progesterone receptor , endocrinology , medicine , androgen receptor , estrogen , menstrual cycle , androgen , progestogen , biology , estrogen receptor , andrology , hormone , population , prostate cancer , cancer , family planning , environmental health , breast cancer , research methodology
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive. However, unscheduled breakthrough bleeding (BTB), leads to discontinuation in a proportion of users. The LNG-IUS down-regulates endometrial progesterone and estrogen receptors and this may play a role in the mechanism responsible for BTB. LNG is an androgenic progestogen and so we examined the regulation of the androgen receptor (AR) in endometrium exposed to intrauterine LNG. Furthermore, as the enzyme 17beta-hydroxysteroid dehydrogenase type 2 (17betaHSD2) regulates intracellular levels of estrogens, progestins and androgens, we evaluated the changes in expression of 17betaHSD2 in the same tissue endometrial samples.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom